Physician profile
Susan Jerian
NPI 1457726440
$274,483.06
in general payments reported to CMS, 2019-2025
14 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $92K · 2021: $16K · 2022: $8,250 · 2023: $7,100 · 2024: $163 · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $65K · Travel and Lodging: $699 · Food and Beverage: $46.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $65,177.08 |
| Travel and Lodging | $699.41 |
| Food and Beverage | $46.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $113,527.60 | 2019-2020 | |
| Aadi Bioscience, INC. | $44,450.00 | 2025 | Fyarro |
| Horizon Therapeutics Plc | $42,904.14 | 2019-2020 | |
| Genentech, INC. | $22,710.19 | 2021-2025 | Columvi, Polivy |
| Biocryst Pharmaceuticals, INC. | $22,295.73 | 2019-2020 | |
| Gilead Sciences, INC. | $13,287.50 | 2019-2023 | |
| Kite Pharma, INC. | $4,750.00 | 2021 | |
| Servier Pharmaceuticals LLC | $4,500.00 | 2021 | |
| Astellas Pharma Global Development | $3,145.40 | 2019 | |
| Janssen Research & Development, LLC | $2,750.00 | 2021 | |
| Biogen, INC. | $162.50 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Jerian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.